Cancer control: Non-DNA changes induce metabolism variations in hepatocellular carcinomas

February 22, 2021

Cancer cells acquire growth advantages over normal cells in myriad ways. Changes in cell programming allow these cells to grow in an uncontrolled fashion, thereby forming the cancer mass. Hepatocellular carcinoma (HCC), being highly malignant and invasive with a high recurrence rate and drug resistant phenotype, is one of the most dreadful cancers. Understanding the underlying molecular mechanisms is crucial to design therapeutic interventions and to predict patient prognosis.

Cancer cells use metabolic, immunogenic, or growth-related strategies, which can be controlled by a number of alterations in the cell process. Of these, "post-transcriptional RNA modification" has recently sparked interest among cancer biologists. N6-methyladenosine (m6A) methylation, a type of RNA modification, remains the most abundant epigenetic (non-DNA related) modification in eukaryotic cells. Abnormal activity of proteins that handle m6A regulation has been linked to cancer hallmarks like invasion, metastasis, and drug resistance in several cancers including HCC. But does this correlation translate into a causative relationship? Can m6A modification influence the behavior of HCC and help predict prognosis?

To find out, a group of researchers from Fudan University, China led by Prof. Lun-Xiu Qin carried out a bioinformatics analysis to identify specific m6A signatures and associated regulators that can help predict metabolic state, disease severity, and prognosis of HCC. Talking about the importance of metabolic alterations, author, Prof. Qin says, "Our previous work has revealed how metabolism dysfunction can affect HCC invasion capacity and can be targeted for therapeutic interventions. Now, we wanted to know how they are caused."

In their new study published in Cancer Biology & Medicine, the researchers used data that collectively reflect epigenetic RNA modifications from public sources - The Cancer Genome Atlas (TCGA) database, the Gene- Expression Ominibus (GEO), and the International Cancer Genome Consortium (ICGC). A total of 605 samples were used. They were able to identify 23 m6A regulators from published literature, of which 13 have been reported in HCC. In addition, they also included m6A regulators linked to other cancers. The regulators were clustered into metabolic groups, and the biological processes across clusters were differentiated. They also developed a novel m6A score to quantify how much modifications happened in HCC, the association with other alterations that contribute to HCC pathogenesis, and the response to treatment with sorafenib (line of treatment for liver cancer).

The results were clear: there was a well-defined heterogeneity in m6A patterns between tumor and non-tumor liver tissues. Moreover, they found considerable differences in copies of the gene along with increased gene expression in m6A regulators across HCC and were able to group HCC cells into 3 clusters with distinct metabolic profiles.

The 3 distinct m6A modification patterns in HCC each had distinct metabolic characteristics. M6A cluster C1, which corresponded to lower expression of m6A regulators was characterized by metabolic hyperactivity, lower tumor stage, better prognosis, and lower response to sorafenib treatment. In contrast, m6A cluster C3 was distinct in its hyperactive mRNA methylations, higher expression of m6A regulators, and was characterized by hypoactive metabolism, advanced tumor stage, poorer prognosis, and a better response to sorafenib. The m6A cluster, C2, was intermediate between C1 and C3.

Highlighting their key findings with respect to HCC prognosis and treatment, authors state, "This is the first work exploring the m6A methylation heterogeneity in HCC. We were also able to identify certain m6A regulators as risk factors for poor prognosis, therefore suggesting the potential of the m6A landscape in predicting disease progression and outcomes."

Overall, this study enhances our understanding of how m6A regulators influence metabolic heterogeneity of HCC and provides novel insights into potential prognostic markers and response to treatment in patients with HCC.
-end-
Reference

Authors: Xiaotian Shen (1,2), Beiyuan Hu (1,2), Jing Xu (3), Wei Qin (1,2), Yan Fu (1,2), Shun Wang (1,2), Qiongzhu Dong (1,2), Lunxiu Qin (1,2)

Title of original paper: The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics

Journal:Cancer Biology & Medicine

DOI: 10.20892/j.issn.2095-3941.2020.0402

Affiliations:

(1) Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, China

(2) Institutes of Biomedical Sciences, Fudan University, China

(3) Shanghai Medical College, Fudan University, China

About Professor Lun-Xiu Qin

Lun-Xiu Qin, MD, PhD, is a Professor and Director at the Department of Surgery, Huashan Hospital, Institute of Cancer Metastasis, Fudan University. He is a founding member of the International Liver Cancer Association and the Chairman of Cancer Precision Treatment Society of China Anti-Cancer Association, among other roles. He is a recipient of many government awards and honors. He focuses on the surgical treatment of hepatobiliary diseases and the translational study of metastatic recurrence of liver cancer. He has published over 130 papers in peer-reviewed English journals.

Cactus Communications

Related Hepatocellular Carcinoma Articles from Brightsurf:

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
Volume 11, Issue 28 of Oncotarget features ''Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation'' by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs.

Oncotarget: GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma
The cover for issue 36 of Oncotarget features Figure 7, 'Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model,' by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood.

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
The cover for issue 27 of Oncotarget features Figure 4, ''(A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period,'' by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

Contrast-enhanced ultrasound predicts nodule transformation to hepatocellular carcinoma
An article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology has identified sonographic biomarkers that can predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma (HCC).

Lifetime indoor tanning associated with squamous cell carcinoma cancer
This observational study used data from nearly 160,000 women in Norway to examine lifetime indoor tanning and risk of squamous cell carcinoma, one of the most common types of cancer worldwide.

Aspirin improves liver function after embolization of hepatocellular carcinoma
Aspirin therapy is associated with both improved liver function test results and survival after transarterial embolization for hepatocellular carcinoma, according to an ahead-of-print article by F.

Percutaneous ablation vs. surgery for hepatocellular carcinoma
Compared to surgery, percutaneous liver ablation interventions (IRs) in patients with hepatocellular carcinoma (HCC) are associated with lower inhospital mortality, length of hospital stay (LOS), and hospitalization costs, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii.

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells.

New combined treatment shows promise in hepatocellular carcinoma
New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival.

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis.

Read More: Hepatocellular Carcinoma News and Hepatocellular Carcinoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.